{"disease":{"id":"agitation-in-patients-with-dementia-of-the-alzheimer-s-type","name":"agitation in patients with dementia of the alzheimer s type"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02446132","title":"Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1197,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03393520","title":"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":601,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":false},{"nct_id":"NCT04947553","title":"A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":456,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05557409","title":"A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":408,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02442765","title":"Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT03226522","title":"Addressing Dementia Via Agitation-Centered Evaluation","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":366,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04464564","title":"Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":241,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04408755","title":"Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":184,"lead_sponsor_name":"Otsuka Pharmaceutical Development & Commercialization, Inc.","has_results":true},{"nct_id":"NCT04797715","title":"Assessing Clinical Outcomes in Alzheimer's Disease Agitation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06736509","title":"An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":139,"lead_sponsor_name":"Axsome Therapeutics, Inc.","has_results":false}],"total":10},"guidelines":[],"source":"Drug Landscape verified database"}